NCT05979298View on ClinicalTrials.gov

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Ovarian CancerPlatinum-resistant Ovarian Cancer
Interventions
DRUG

Gemcitabine

Chemotherapeutics

BIOLOGICAL

ELENAGEN

DNA plasmid

Trial Locations (1)

Unknown

Minsk City Clinical Oncology Center, Minsk

Sponsors

Lead Sponsor

CureLab Oncology
All Listed Sponsors
lead

CureLab Oncology

INDUSTRY

NCT05979298 - Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter